N-Boc-吲哚啉-7-甲醛 | 174539-67-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: N-Boc-吲哚啉-7-甲醛
• 中文别名: 1-(叔丁氧羰基)吲哚啉-7-甲醛；N-BOC-吲哚啉-7-甲醛
• 英文名称: 1-(tert-butoxycarbonyl)-7-indolinecarboxaldehyde
• 英文别名: tert-butyl 7-formylindoline-1-carboxylate；N-Boc-indoline-7-carboxaldehyde；tert-butyl 7-formyl-2,3-dihydro-indol-1-carboxylate；tert-butyl 7-formyl-2,3-dihydroindole-1-carboxylate
• CAS: 174539-67-4
• 化学式: C₁₄H₁₇NO₃
• mdl: MFCD02187200
• 分子量: 247.294
• InChiKey: KUYIMEZLCAWOMI-UHFFFAOYSA-N

物化性质

• 熔点：
  86-90 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  T
• 安全说明：
  S45
• 危险类别码：
  R25
• 海关编码：
  2933990090
• WGK Germany：
  3
• 危险标志：
  GHS06
• 危险品运输编号：
  UN 2811 6.1/PG 3
• 危险性描述：
  H300,H319
• 危险性防范说明：
  P264,P301 + P310,P305 + P351 + P338

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : N-Boc-indoline-7-carboxaldehyde
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 174539-67-4
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 2), H300
Eye irritation (Category 2), H319
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
T Toxic R25
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H300 Fatal if swallowed.
H319 Causes serious eye irritation.
Precautionary statement(s)
P264 Wash hands thoroughly after handling.
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Synonyms : 1-(tert-Butoxycarbonyl)indoline-7-carboxaldehyde
Formula : C14H17NO3
Molecular Weight : 247,29 g/mol
CAS-No. : 174539-67-4
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
N-Boc-indoline-7-carboxaldehyde
CAS-No. 174539-67-4 Acute Tox. 2; H300 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
N-Boc-indoline-7-carboxaldehyde
CAS-No. 174539-67-4 T, R25 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 86 - 90 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,685
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (N-Boc-indoline-7-carboxaldehyde)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (N-Boc-indoline-7-carboxaldehyde)
IATA: Toxic solid, organic, n.o.s. (N-Boc-indoline-7-carboxaldehyde)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-Boc-吲哚啉-7-甲醛 在 三苯基膦 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 7-(2,2-dibromovinyl)-2,3-dihydro-1H-indole
  参考文献：
  名称：

  Rapid, robust, clean, catalyst-free synthesis of 2-halo-3-carboxyindoles

  摘要：

  A novel synthesis of 2-halo-3-carboxyindoles from 2-(2,2-dihalovinyl)anilines was discovered. Reaction conditions and substrate applicability were studied. Optimally, the reaction takes only minutes when these substrates are heated in DMSO at 120 degrees C in the presence of cesium carbonate. However, the reaction is robust and takes place at a wide range of temperatures, is tolerant of aqueous reaction conditions, and can be performed in a variety of polar solvent/carbonate base combinations where the limiting factor is base solubility. A wide range of substituents is tolerated on the 2-(2,2-dihalovinyl)anilines, and yields are generally high, requiring only acidic aqueous work-up to obtain pure products. No catalyst is required for the transformation. The mechanism is believed to involve initial formation of an alkynyl bromide intermediate followed by ring closure and carbon dioxide trapping, leading to product formation. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2011.02.037
• 作为产物：
  描述：

  1-Boc-吲哚啉 、 N,N-二甲基甲酰胺 在 四甲基乙二胺 、 仲丁基锂 、 氯化铵 作用下， 以 乙醚 、 环己烷 为溶剂， 反应 0.5h， 以69%的产率得到N-Boc-吲哚啉-7-甲醛
  参考文献：
  名称：

  SYNTHESIS OF 7-SUBSTITUTED INDOLINES via DIRECTED LITHIATION OF 1-(tert-BUTOXYCARBONYL)INDOLINE: 7-INDOLINECARBOXALDEHYDE

  摘要：

  DOI：

  10.15227/orgsyn.073.0085

文献信息

• Unveiling RNA‐Binding Properties of Verapamil and Preparation of New Derivatives as Inhibitors of HIV‐1 Tat‐TAR Interaction
  作者：Céline Martin、Serena De Piccoli、Marc Gaysinski、Cécile Becquart、Stéphane Azoulay、Audrey Di Giorgio、Maria Duca

  DOI：10.1002/cplu.201900650

  日期：2020.1

  therapeutic applications since coding and non‐coding RNAs bear a pivotal role both in viral and bacterial infections as well as in human pathologies such as cancer. Here, we focused on the targeting of HIV‐1 TAR RNA as a promising target for the development of new anti‐HIV therapies but also as an ideal model to validate the discovery of original RNA ligands. First, we performed an initial screening of a

  由于编码和非编码RNA在病毒和细菌感染以及人类病理疾病（例如癌症）中都起着关键作用，因此现在已经确立了使用小分子靶向RNA的许多治疗应用前景非常广阔的策略。在这里，我们专注于将HIV-1 TAR RNA作为开发新的抗HIV疗法的有希望的目标，同时也是验证原始RNA配体发现的理想模型。首先，我们对抗TAR的化合物库进行了初步筛选，从而发现了市售的钙通道阻滞剂维拉帕米，作为开发新RNA配体的有前途的化学结构。一系列维拉帕米类似物的合成导致了有希望的结构活性关系，并导致了化合物2h的发现，维拉帕米与吲哚片段之间的结合物，作为一种有效且选择性的TAR结合物，能够抑制Tat / TAR相互作用，IC50为18.8 µM。这项工作为发现原始和选择性的RNA配体提供了库筛选的潜力，并说明了如何仍需要研究针对蛋白质靶标的现有药物进行RNA结合，这是小分子靶向RNA领域中的一种有前途的策略。
• [EN] 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE 3-(5-MÉTHOXY-1-OXOISOINDOLIN-2-YL)PIPÉRIDINE-2,6-DIONE ET LEURS UTILISATIONS
  申请人：NOVARTIS AG

  公开号：WO2021124172A1

  公开（公告）日：2021-06-24

  The present disclosure relates to compounds of formula (I') and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.

  本公开涉及式(I')的化合物、药物组合物及其在降低广泛间隔锌指蛋白结构域（WIZ）表达水平、诱导胎儿血红蛋白（HbF）表达以及治疗遗传性血液疾病（例如，血红蛋白病，例如，β-血红蛋白病）方面的用途，如镰状细胞病和β-地中海贫血。
• Puckering the Planar Landscape of Fragments: Design and Synthesis of a 3D Cyclobutane Fragment Library
  作者：David J. Hamilton、Marieke Beemsterboer、Caroline M. Carter、Jasmina Elsayed、Rilana E. M. Huiberts、Hanna F. Klein、Peter O'Brien、Iwan J. P. Esch、Maikel Wijtmans

  DOI：10.1002/cmdc.202200113

  日期：2022.5.4

  33-member library with three-dimensional cyclobutane fragments is described. Principle component analysis, the fragment rule-of-three, and principal moment of inertia analysis guided design to produce diastereomerically-pure cis/trans isomers with three functional groups: amines, amides and sulfonamides. Calculated physicochemical and 3D properties of the library are deemed attractive for fragment screening

  描述了一个包含 33 个成员的具有三维环丁烷片段的库。主成分分析、片段三规则和主惯性矩分析指导设计以生产具有三个官能团的非对映体纯顺式/反式异构体：胺、酰胺和磺酰胺。文库的计算物理化学和 3D 特性被认为对片段筛选具有吸引力。
• SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS
  申请人：——

  公开号：US20040092502A1

  公开（公告）日：2004-05-13

  The present invention is directed to certain novel compounds represented by structural Formula (I) 1 or pharmaceutically acceptable salt forms thereof, wherein R 1 , R 6a , R 6b , R 7 , R 8 , R 9 , X, b, m, and n are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

  本发明涉及由结构式（I）1表示或其药学上可接受的盐形式的某些新型化合物，其中R1、R6a、R6b、R7、R8、R9、X、b、m和n在此描述。本发明还涉及包含这些新型化合物作为活性成分的制药配方以及利用这些化合物和它们的配方治疗某些疾病。本发明的化合物是5-羟色胺激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症、焦虑症、抑郁症、精神病、精神分裂症、睡眠障碍、性功能障碍、偏头痛、与头痛有关的疾病、社交恐惧症以及胃肠道疾病，如胃肠道运动功能障碍。
• Trisubstituted amine compound
  申请人：Nakamura Yoshinori

  公开号：US20090023729A1

  公开（公告）日：2009-01-22

  The present invention relates to a compound of the general formula (1): wherein, Y is a methylene group, and the like; A is an optionally substituted heterocyclic group, and the like; B is an optionally substituted heterocyclic group, and the like; R 1 is an optionally substituted alkyl group, wherein the alkyl group further may optionally be substituted by an optionally substituted homocyclic group, and the like; and R 2 is an optionally substituted amino group, and the like; or a pharmaceutically acceptable derivative thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP), thereby being useful for prophylaxis and/or treatment of arteriosclerotic diseases, hyperlipemia or dyslipidemia, and the like.

  本发明涉及一种通式（1）的化合物：其中，Y是亚甲基基团等；A是可选取的取代的杂环基团等；B是可选取的取代的杂环基团等；R1是可选取的取代的烷基团，其中该烷基团还可选择性地被可选取的取代的同环基团等所取代；而R2是可选取的取代的氨基团等；或其药学上可接受的衍生物，其具有对胆固醇酯转移蛋白（CETP）的抑制活性，因此可用于预防和/或治疗动脉硬化性疾病、高脂血症或血脂异常等。